The short version of 冻干粉 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-21. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Henriksen played the android Bishop in Cameron's film Aliens (1986), and as Bishop's designer Michael Weyland in Alien 3 (1992). He also played Charles Bishop Weyland, the man upon whom Bishop was based, in Alien vs. Predator (2004). Bill Paxton and Henriksen are the only actors whose characters were killed by the Terminator, the Alien, and the Predator. He played the vampire leader Jesse Hooker in Kathryn Bigelow's cult film Near Dark. He portrayed gunfighters in the Westerns Dead Man and The Quick and the Dead, and appeared with British actor Bruce Payne in Aurora: Operation Intercept in 1995. That year, he also played Sheriff Doug Barnum in the film Powder. He appeared with Payne again in Face the Evil (1997), and the dystopian classic Paranoia 1.0 (2004). In 1996, Henriksen starred in the television series Millennium, created and produced by Chris Carter, the creator of The X-Files. Henriksen played Frank Black, a former FBI agent who possessed a unique ability to see into the minds of killers. Carter created the role specifically for the actor. His performances on Millennium earned him critical acclaim, a People's Choice Award nomination for Favorite New Male TV Star, and three consecutive Golden Globe nominations for Best Performance by an Actor in a TV Series (1997–1999). The series was canceled in 1999. On television, Henriksen appeared in the ensemble of Into the West (2005), a miniseries executive-produced by Steven Spielberg. He appeared in a Brazilian soap opera, Caminhos do Coração (Ways of the Heart) from Rede Record, aired in 2007–2008.
=== Research === A major source of bubble instability is when a wide variety of sizes of bubbles are created, gases in smaller bubbles diffuses or disperses into larger bubbles. This is due to their differing Laplace pressures. As of 2023, technologies to control bubble size, distribution and movement were difficult to employ during production. "Advanced" research was underway, including by companies such as Nestlé. In 2013, scientists released the results of experimental research on the impact of phospholipids on aerating cocoa butter. The research found that although all phospholipids tested made cocoa butter foam more, the foam's stability varied by type of phospholipid. The final cocoa butter was also observed to be more stable when the process was undertaken at lower temperatures.
==== Cuba (1955-56) ==== In the winter of 1955–56, Mizell resumed his professional baseball career in Cuba, where he emerged as one of the Cuban League's most popular players. He set records for most strikeouts in a game (15) and in a season (206). With a 12–9 record and a 2.16 ERA, he finished second in most valuable player (MVP) voting. In February, his wife gave birth to their first son. Mizell found out during one of the games and, according to one story, was so excited that he absentmindedly went to hit holding his glove instead of a baseball bat.
Sources: en.wikipedia.org
2003 saw Helton involved in the closest NL batting race in history, as he hit .35849, while St. Louis Cardinals first baseman Albert Pujols edged him out by posting a .35871 batting average to win the batting crown. Helton also had 33 home runs, 117 RBI, 135 runs, 49 doubles and five triples. He won his fourth Player of the Month honor for April, when he hit .337 with six home runs, 27 RBI, 28 runs, 11 doubles and 24 walks. He also appeared in his fourth consecutive All-Star Game. During the 2004 season, Helton again finished second in the NL batting race, as he hit .347, while San Francisco Giants left fielder Barry Bonds hit .362. Helton also had 32 home runs and 96 RBI on the season. He became the first player in MLB history to hit at least .315 with 25 home runs and 95 RBI in each of his first seven full seasons in the majors. He became only the third player in MLB history to accomplish that feat during any seven-year stretch in a career (Lou Gehrig and Babe Ruth are the others). He set a franchise record by hitting at least 30 home runs in six consecutive seasons. Helton was named to his team-record fifth consecutive All-Star Game and won his third Gold Glove during the season. In 2005, Helton was placed on the disabled list (July 26 – August 9) for the first time in his career, missing time with a strained left calf muscle. He hit .320 with 20 home runs, 79 RBI, 92 runs, and 45 doubles for the season. He was under 1.000 in OPS (finished with .979 OPS) for the first time since 1999, and was also left off the NL All-Star roster for the first time since that same year.
=== Origins === The Centre Party belongs to the political spectrum of "Political Catholicism" that, emerging in the early 19th century after the turmoil of the Napoleonic wars, had changed the political face of Germany. Many Catholics found themselves in Protestant dominated states. The first major conflict between the Catholic Church and a Protestant state was the "Colonian Church conflict", when the Prussian government interfered in the question of mixed marriages and the religious affiliation of children resulting from these. This led to serious aggressions against the Catholic population of the Rhineland and Westphalia and culminated in the arrest of the Archbishop of Cologne. At that time, one of the founding fathers of Political Catholicism was journalist Joseph Görres, who called upon Catholics to "stand united" for their common goals, "religious liberty and political and civil equality of the denominations". The conflict relaxed after 1840, with Frederick William IV's accession to the throne. The German revolutions of 1848–1849 brought new opportunities for German Catholics. In October, the bishops had their first meeting in 40 years in Würzburg and the local "Catholic Federations" assembled in Mainz to found the "Catholic Federation of Germany". In the National Assembly, which was convened to draw up a German constitution, a "Catholic club" was formed. This was not yet a comprehensive party, but a loose union aimed at protecting the Church's liberties in a future Germany, supported by many petitions from the "[Pope] Pius federations for religious liberty".
=== Antivenom === Until the advent of antivenom, bites from some species of snake were almost universally fatal. Despite huge advances in emergency therapy, antivenom is often still the only effective treatment for envenomation. The first antivenom was developed in 1895 by French physician Albert Calmette for the treatment of Indian cobra bites. Antivenom is made by injecting a small amount of venom into an animal (usually a horse or sheep) to initiate an immune system response. The resulting antibodies are then harvested from the animal's blood. Antivenom is injected into the person intravenously, and works by binding to and neutralizing venom enzymes. It cannot undo the damage already caused by venom, so antivenom treatment should be sought as soon as possible. Modern antivenoms are usually polyvalent, making them effective against the venom of numerous snake species. Pharmaceutical companies that produce antivenom target their products against the species native to a particular area. The availability of antivenom is a major concern in some areas, including most of Africa, due to economic reasons (antivenom crisis). In Sub-Saharan Africa, the efficacy of antivenom is often poorly characterised and some of the few available products have even been found to lack effectiveness. Although some people may develop serious adverse reactions to antivenom, such as anaphylaxis, in emergency situations this is usually treatable in a hospital setting and hence the benefit outweighs the potential consequences of not using antivenom.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.